The first crop in Maryland’s long-delayed medical cannabis program is mature and waiting for testing, but it is still unclear when patients might be able to buy it.
And industry officials caution that when it is ready for sale, there will not be nearly enough to meet market demand.
“This industry is in its infancy,” Patrick Jameson, executive director of the Maryland Medical Cannabis Commission, said Tuesday. “No one should have any expectations,” he said. “The initial supply of medical cannabis will be limited.”
Click here to read the complete article
Erin Cox ~ BaltimoreSun.com ~
